{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:01:08Z","timestamp":1786132868533,"version":"build-2736575974"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract.<\/jats:title>\n                    <jats:p>\n                      19-Nor-1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>2<\/jats:sub>\n                      , an analog of 1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>3<\/jats:sub>\n                      , is used to treat secondary hyperparathyroidism because it suppresses parathyroid hormone synthesis and secretion with lower calcemic and phosphatemic activities. 19-Nor-1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>2<\/jats:sub>\n                      is approximately 10 times less active than 1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>3<\/jats:sub>\n                      in promoting bone resorption, which accounts in part for the low potency of this analog in increasing serum calcium and phosphorus. Concern that 19-nor-1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>2<\/jats:sub>\n                      also could be less potent than 1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>3<\/jats:sub>\n                      on bone formation led to a comparison of the potency of both compounds on osteoblasts. In the human osteoblast-like cell line MG-63, 1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>3<\/jats:sub>\n                      and 19-nor-1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>2<\/jats:sub>\n                      had a similar potency in upregulating vitamin D receptor content and suppressing proliferation. Both sterols caused a similar reduction in DNA content and proliferating cell nuclear antigen protein expression. Time-course and dose-response studies on 1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>3<\/jats:sub>\n                      and 19-nor-1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>2<\/jats:sub>\n                      induction of the marker of bone formation, osteocalcin, showed overlapping curves. The effects on alkaline phosphatase (ALP) activity also were studied in MG-63 cells that had been co-treated with either sterol and transforming growth factor-\u03b2, an enhancer of 1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>3<\/jats:sub>\n                      \u2014induced ALP activity in this cell line. Transforming growth factor-\u03b2 alone had no effect, whereas 1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>3<\/jats:sub>\n                      and 19-nor-1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>2<\/jats:sub>\n                      increased ALP activity similarly. These studies demonstrate that 19-nor-1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>2<\/jats:sub>\n                      has the same potency as 1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>3<\/jats:sub>\n                      not only in inducing vitamin D receptor content, osteocalcin levels, and ALP activity but also in controlling osteoblastic growth. Therefore, it is unlikely that 19-nor-1,25-(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D\n                      <jats:sub>2<\/jats:sub>\n                      would have deleterious effects on bone remodeling.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.v1271468","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T19:45:25Z","timestamp":1619466325000},"page":"1468-1474","source":"Crossref","is-referenced-by-count":22,"title":["Relative Potencies of 1,25-(OH)2D3 and 19-Nor-1,25-(OH)2D2 on Inducing Differentiation and Markers of Bone Formation in MG-63 Cells"],"prefix":"10.1681","volume":"12","author":[{"given":"JANE L.","family":"FINCH","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ADRIANA S.","family":"DUSSO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TRICIA","family":"PAVLOPOULOS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EDUARDO A.","family":"SLATOPOLSKY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-200107000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:25:16Z","timestamp":1786130716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-200107000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.v1271468","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}